Vigeo attenuates cartilage and bone destruction in a collagen‑induced arthritis mouse model by reducing production of pro‑inflammatory cytokines

Cheon,Yoon-Hee; Lee,Chang Hoon; Eun,So Young; Park,Gyeong Do; Chung,Chong Hyuk; Kim,Ju-Young; Lee,Myeung Su

doi:10.3892/etm.2024.12496

Vigeo attenuates cartilage and bone destruction in a collagen‑induced arthritis mouse model by reducing production of pro‑inflammatory cytokines

Authors:
- Yoon-Hee Cheon
- Chang Hoon Lee
- So Young Eun
- Gyeong Do Park
- Chong Hyuk Chung
- Ju-Young Kim
- Myeung Su Lee
View Affiliations

Affiliations: Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea
Published online on: March 19, 2024 https://doi.org/10.3892/etm.2024.12496
Article Number: 208
Copyright: © Cheon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease characterized by articular cartilage destruction, bone destruction and synovial hyperplasia. It has been suggested that Vigeo, a mixture of Eleutherococcus senticosus, Achyranthes japonica and Atractylodes japonica fermented with Korean nuruk, has an anti‑osteoporotic effect in a mouse model of inflammation‑mediated bone loss. The present study evaluated the therapeutic effects of Vigeo in RA using a collagen‑induced arthritis (CIA) mouse model. DBA/1J mice were immunized with bovine type II collagen on days 0 and 21 and Vigeo was administered daily for 20 days beginning the day after the second type II collagen injection. The mice were sacrificed on day 42 and the joint tissues were anatomically separated and subjected to micro computed tomography and histological analyses. In addition, the serum levels of TNF‑α, IL‑6 and IL‑1β were determined by enzyme‑linked immunosorbent assays. CIA in DBA/1J mice caused symptoms of RA, such as joint inflammation, cartilage destruction and bone erosion. Treatment of CIA mice with Vigeo markedly decreased the symptoms and cartilage pathology. In addition, radiological and histological analyses showed that Vigeo attenuated bone and cartilage destruction. The serum TNF‑α, IL‑6 and IL‑1β levels following oral Vigeo administration were also reduced when compared with those in CIA mice. The present study revealed that Vigeo suppressed arthritis symptoms in a CIA‑RA mouse model, including bone loss and serum levels of TNF‑α, IL‑6 and IL‑1β.

View Figures

View References

1	Aletaha D and Smolen JS: Diagnosis and management of rheumatoid arthritis: A review. JAMA. 320:1360–1372. 2018.PubMed/NCBI View Article : Google Scholar
2	Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 423:356–361. 2003.PubMed/NCBI View Article : Google Scholar
3	Wu CY, Yang HY and Lai JH: Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: Biological effects and mechanisms of immunopathogenesis. Int J Mol Sci. 21(4015)2020.PubMed/NCBI View Article : Google Scholar
4	Petrelli F, Mariani FM, Alunno A and Pexeddu I: Pathogenesis of rheumatoid arthritis: One year in review 2022. Clin Exp Rheumatol. 40:475–482. 2022.PubMed/NCBI View Article : Google Scholar
5	Kondo N, Kuroda T and Kobayashi D: Cytokine networks in the pathofenesis of rheumatoid arthritis. Int J Mol Sci. 22(10922)2021.PubMed/NCBI View Article : Google Scholar
6	Romas E, Gillespie MT and Martin TJ: Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 30:340–346. 2002.PubMed/NCBI View Article : Google Scholar
7	Rossi JF, Lu ZY, Jourdan M and Klein B: Interleukin-6 as a therapeutic target. Clin Cancer Res. 21:1248–1257. 2015.PubMed/NCBI View Article : Google Scholar
8	Pandolfi F, Franza L, Carsi V, Altamura S, Andriollo G and Nucera E: Interleukin-6 in rheumatoid arthritis. Int J Mol Sci. 21(5238)2020.PubMed/NCBI View Article : Google Scholar
9	Li B, Wang P, Jiao J, Wei H, Xu W and Zhou P: Roles of the RANKL-RANK axis in immunity-implications for pathogenesis and treatment of bone metastasis. Front Immunol. 13(824117)2022.PubMed/NCBI View Article : Google Scholar
10	Levescot A, Chang MH, Schnell J, Nelson-Maney N, Yan J, Martínez-Bonet M, Grieshaber-Bouyer R, Lee PY, Wei K, Blaustein RB, et al: IL-1β-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J Clin Invest. 131(e141008)2021.PubMed/NCBI View Article : Google Scholar
11	Allard-Chamard H, Carrier N, Dufort P, Durand M, de Brum-Fernandes AJ, Boire G, Komarova SV, Dixon SJ, Harrison RE, Manolson MF and Roux S: Osteoclasts and their circulating precursors in rheumatoid arthritis: Relationships with disease activity and bone erosions. Bone Rep. 12(100282)2020.PubMed/NCBI View Article : Google Scholar
12	Eun SY, Cheon YH, Park GD, Chung CH, Lee CH, Kim JY and Lee MS: Anti-osteoporosis effects of the Eleutherococcus senticosus, Achyranthes japonica, and Atractylodes japonica mixed extract fermented with nuruk. Nutrients. 13(3904)2021.PubMed/NCBI View Article : Google Scholar
13	Perilli E, Cantley M, Marino V, Crotti TN, Smith MD, Haynes DR and Dharmapatni AASSK: Quantifying not only bone loss, but also soft tissue swelling, in a murine inflammatory arthritis model using micro-computed tomography. Scand J Immunol. 81:142–150. 2015.PubMed/NCBI View Article : Google Scholar
14	Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H and Vinderola G: The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 18:649–667. 2021.PubMed/NCBI View Article : Google Scholar
15	Shen B: A new golden age of natural products drug discovery. Cell. 163:1297–1300. 2015.PubMed/NCBI View Article : Google Scholar
16	Chen GQ and Liu X: On the future fermentation. Microb Biotechnol. 14:18–21. 2021.PubMed/NCBI View Article : Google Scholar
17	Shah AA, Qian C, Liu Z, Wu J, Sultana N, Mobashar M, Wanapat M and Zhong X: Evaluation of biological and chemical additives on microbial community, fermentation characteristics, aerobic stability, and in vitro gas production of SuMu No. 2 elephant grass. J Sci Food Agric. 101:5429–5436. 2021.PubMed/NCBI View Article : Google Scholar
18	Ramírez-Rendon D, Passari AK, Ruiz-Villafán B, Rodríquez-Sanoja R, Sánchez S and Demain AL: Impact of novel microbial secondary metabolites on the pharma industry. Appl Microbiol Biotechnol. 106:1855–1878. 2022.PubMed/NCBI View Article : Google Scholar
19	Orange DE, Blachere NE, DiCarlo EF, Mirza S, Pannellini T, Jiang CS, Frank MO, Parveen S, Figgie MP, Gravallese EM, et al: Rheumatoid arthritis morning stiffness is associated with synovial fibrin and neutrophils. Arthritis Rheumatol. 72:557–564. 2020.PubMed/NCBI View Article : Google Scholar
20	Zhang A and Lee YC: Mechanisms for joint pain in rheumatoid arthritis (RA): From cytokines to central sensitization. Curr Osteoporos Rep. 16:603–610. 2018.PubMed/NCBI View Article : Google Scholar
21	Cai W, Gu Y, Cui H, Cao Y, Wang X, Yao Y and Wang M: The efficacy and safety of mainstream medications for patients with cDMARD-Naïve rheumatoid arthritis: A network meta-analysis. Front Pharmacol. 9(183)2018.PubMed/NCBI View Article : Google Scholar
22	Simon LS and Yocum D: New and future drug therapies for rheumatoid arthritis. Rheumatology (Oxford). 39 (Suppl 1):S36–S42. 2000.PubMed/NCBI View Article : Google Scholar
23	Lim DW, Kim JG, Lee YS, Cha SH and Kim YT: Preventive effects of Eleutherococcus senticosus bark extract in OVX-induced osteoporosis in rats. Molecules. 18:7998–8008. 2013.PubMed/NCBI View Article : Google Scholar
24	Kim JS, Lee SW, Kim SK, Na SW and Kim YO: Osteoprotective effect of extract from Achyranthes japonica in ovariectomized rats. J Exerc Rehabil. 10:372–377. 2014.PubMed/NCBI View Article : Google Scholar
25	Ha H, An H, Shim KS, Kim T, Hwang YH and Ma JY: Ethanol extract of Atractylodes macrocephala protects bone loss by inhibiting osteoclast differentiation. Molecules. 18:7376–7388. 2013.PubMed/NCBI View Article : Google Scholar
26	Choy EH and Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 344:907–916. 2001.PubMed/NCBI View Article : Google Scholar
27	Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D and Kollias G: Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10:4025–4031. 1991.PubMed/NCBI View Article : Google Scholar
28	Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen J, Wagner EF and Schett G: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 110:1419–1427. 2002.PubMed/NCBI View Article : Google Scholar
29	Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE and Song SYR: Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 4(R7)2002.PubMed/NCBI View Article : Google Scholar
30	Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, Fujikawa K and Tada N: Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest. 107:1127–1135. 2001.PubMed/NCBI View Article : Google Scholar
31	Thomson BM, Saklatvala J and Chambers TJ: Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. J Exp Med. 164:104–112. 1986.PubMed/NCBI View Article : Google Scholar
32	Okamoto H, Yamamura M, Morita Y, Harada S, Makino H and Ota Z: The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 40:1096–1105. 1997.PubMed/NCBI View Article : Google Scholar
33	Kobayashi H, Ohshima S, Nishioka K, Yamaguchi N, Umeshita-Sasai M, Ishii T, Mima T, Kishimoto T, Kawase I and Saeki Y: Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA. J Rheumatol. 29:1176–1182. 2002.PubMed/NCBI
34	Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M and Kishimoto T: Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 95:8222–8226. 1998.PubMed/NCBI View Article : Google Scholar
35	Boe A, Baiocchi M, Carbonatto M, Papoian R and Serlupi-Crescenzi O: Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. 11:1057–1064. 1999.PubMed/NCBI View Article : Google Scholar